Clinical trials sponsored by Axsome Therapeutics, Inc.

Phase breakdown

Conditions studied

Recruiting trials led by Axsome Therapeutics, Inc.

• A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
  NCT06223880 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 40 locations
• Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
  NCT07398417 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
  NCT07717879 · Phase: Phase 3 · Ages: 6 Years to 11 Years · Sex: All (male and female) · 23 locations
• Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
  NCT07717892 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 24 locations

Common questions

How many trials is Axsome Therapeutics, Inc. recruiting for?

Axsome Therapeutics, Inc. is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.